Yourgene Health PLC Directorate Change (4526Z)
January 25 2022 - 01:00AM
UK Regulatory
TIDMYGEN
RNS Number : 4526Z
Yourgene Health PLC
25 January 2022
Yourgene Health plc
("Yourgene" or the "Group" or the "Company")
Directorate Change
Manchester , UK - 25 January 2022: Yourgene (AIM: YGEN), a
leading international molecular diagnostic group, announces the
appointment of Mary Tavener as a Non-executive Director ("NED") and
Chair of the Audit Committee at Yourgene with effect from
today.
Mary has extensive experience in the healthcare sector, having
previously been Chief Financial Officer and board member of AIM
listed Advanced Medical Solutions plc ("AMS") for 19 years during
which the company saw 15 years of consecutive growth. Mary is a
Member of the Chartered Institute of Management Accountants (ACMA)
and a Fellow of the Association of Corporate Treasurers (FCT). Mary
has a degree in Chemistry from the University of Oxford.
Mary is also a Senior Independent NED of Abingdon Health and NED
for Allergy Therapeutics plc.
Separately the Group announces that Nick Mustoe has left the
Board with immediate effect. We wish to thank Nick for all his
support during his time at Yourgene and wish him the best for the
future.
Adam Reynolds, Non-Executive Chairman, commented: "Mary has
extensive experience within the life sciences sector on AIM, which
will be invaluable to the Group as we grow and expand. I look
forward to working alongside Mary as we continue to engage with our
extensive pipeline of exciting opportunities.
"I would also like to thank Nick for his time and support of the
Group. Nick has worked with Yourgene since the Company's IPO in
2014 and we have greatly benefitted from his expertise and
guidance. Nick remains a supportive shareholder in Yourgene and I
wish him all the best in his future endeavours."
Disclosures in accordance with the AIM Rules
Pursuant to Rule 17 and Schedule 2(g) of the AIM Rules for
Companies, the following information is disclosed in respect of
Mary Geraldine Tavener (aged 60):
Current appointments Former appointments in the last
5 years
Abingdon Health PLC Advanced Medical Solutions Group
plc
Allergy Therapeutics PLC Advanced Healthcare Systems
Ltd
Advanced Medical Solutions (Europe)
Ltd
Advanced Medical Solutions (Plymouth)
Ltd
Advanced Medical Solutions (UK)
Ltd
Advanced Medical Solutions BV
Advanced Medical Solutions Germany
GmBH
Advanced Medical Solutions Limited
Advanced Medical Solutions USA
inc
AMS Trustee Company Ltd
Cuddington and Sandiway Playing
Fields Association Ltd
Innovative Technologies Limited
Medlogic Global Holdings Ltd
MPN Medizin Produkte Neustadt
GmBH
Resorba Medical GmBH
Mary Tavener does not hold any share or options in the
Company.
There are no further disclosures required in accordance with AIM
Rule 17 and Schedule Two paragraph (g) of the AIM Rules for
Companies.
Yourgene Health plc Tel: +44 (0)161 669 8122
Lyn Rees, Chief Executive Officer investors@yourgene-health.com
Barry Hextall, Chief Financial Officer
Joanne Cross, Director of Marketing
Singer Capital Markets (Joint Corporate Tel: +44 (0)20 7496 3000
Broker)
Aubrey Powell / Tom Salvesen / George
Tzimas
Stifel Nicolaus Europe Limited (Joint Tel: +44 (0)20 7710 7600
Corporate Broker)
Nicholas Moore / Matthew Blawat / Ben
Maddison
Walbrook PR Ltd (Media and Investor Tel: +44 (0)20 7933 8780 or yourgene@walbrookpr.com
Relations)
Paul McManus / Alice Woodings Mob: 07980 541 893 / 07407 804 654
About Yourgene Health
Yourgene Health is an international molecular diagnostics group
which develops integrated genomic technologies and services
enabling precision medicine. The group works in partnership with
global leaders in DNA technology to advance diagnostic science.
Yourgene primarily develops, manufactures, and commercialises
simple and accurate molecular diagnostic solutions, for
reproductive health, precision medicine and now infectious
diseases. The Group's flagship products include non-invasive
prenatal tests (NIPT) for Down's Syndrome and other genetic
disorders, Cystic Fibrosis screening tests, invasive rapid
aneuploidy tests, and a recent extension into the oncology space
with DPYD genotyping.
The launch of Yourgene Genomic Services has enabled Yourgene to
offer a global laboratory service network equipped to be a full
life-cycle partner for clinical, research and pharmaceutical
organisations to support partners at the preclinical, clinical, and
post-market stages to develop, manufacture, obtain regulatory
approval and commercialise new products and services. In addition,
Yourgene Genomic Services offers an NIPT and high throughput COVID
testing service.
In August 2020, Yourgene acquired Coastal Genomics , Inc., a
sample preparation technology company based in Vancouver, Canada,
enabling the Company to extend its offering and IP portfolio in the
DNA sample preparation sector. The acquisition increased Yourgene's
geographical penetration into the US and Canada, supplementing
existing coverage in the UK, Europe, MEA and Asia.
Yourgene Health is headquartered in Manchester, UK with offices
in Taipei, Singapore, the US and Canada, and is listed on the
London Stock Exchange's AIM market under the ticker "YGEN". For
more information visit www.yourgene-health.com and follow us on
twitter @Yourgene_Health.
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
BOAGZGZMGDLGZZZ
(END) Dow Jones Newswires
January 25, 2022 02:00 ET (07:00 GMT)
Yourgene Health (LSE:YGEN)
Historical Stock Chart
From Feb 2024 to Mar 2024
Yourgene Health (LSE:YGEN)
Historical Stock Chart
From Mar 2023 to Mar 2024